NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received prior treatment with an immune checkpoint inhibitor (i.e., pembrolizumab/Keytruda, atezolizumab/Tecentriq)
Exclusions: Patients with known, unstable, symptomatic brain metastases requiring steroids- see trial for details;

Comments are closed.

Up ↑